MacCoss - Acarbose Paper

MacCoss - Acarbose Paper
Acarbose improves late-life physical function in mice of both sexes, but rejuvenates cardiac structure and lipid profile in males only
Data License: CC BY 4.0 | ProteomeXchange: PXD017706
  • Organism: Mus musculus
  • Instrument: Orbitrap Fusion Lumos
  • SpikeIn: No
  • Keywords: data independent acquisition, Type 2 diabetes, acarbose, age-related disease
  • Lab head: Michael MacCoss Submitter: Gennifer Merrihew
Abstract
With an expanding aging population burdened with comorbidities, there is considerable interest in treatments that optimize health in later life. Acarbose (ACA), a drug used clinically to treat Type 2 diabetes (T2DM) can extend mouse lifespan, with greater effect in males than in females. Utilizing a genetically heterogeneous mouse model, we tested the ability of ACA to ameliorate functional, pathological and biochemical changes that occur during aging, and determined which of the effects of age and drug were sex-dependent. In both sexes, ACA prevented age-dependent loss of body mass, in addition to improving grip strength, balance/coordination on an accelerating rotarod, and rotarod endurance. Age-related cardiac hypertrophy was seen only in male mice, and this male-specific aging effect was attenuated by ACA. ACA-sensitive cardiac changes were associated with reduced activation of cardiac growth promoting pathways and decreased abundance of peroxisomal proteins involved in lipid metabolism. ACA further ameliorated age-associated changes in cardiac lipid species, particularly lysophospholipids – changes which have previously been associated with aging, cardiac dysfunction and cardiovascular disease in humans. In the liver, ACA had pronounced effects on lipid handling in both sexes, reducing hepatic lipidosis during aging and shifting the liver lipidome in adulthood, particularly favoring reduced triglyceride accumulation. Our results demonstrate that ACA, already in clinical use for T2DM, has broad-ranging anti-aging effects in multiple tissues, and may have the potential to increase physical function and alter lipid biology to preserve or improve health at older ages.
Experiment Description
Lysis/Digestion - Mouse heart tissue previously probe sonicated in 90 ul of 0.1% RapiGest in 100 mM Tris with phosphatase inhibitors was resuspended in 30 ul of 3X lysis buffer for a final concentration of 5% SDS, 50mM Triethylammonium bicarbonate (TEAB), 2mM MgCl2, 1X HALT phosphatase and protease inhibitors and vortexed. Protein concentration was measured with a BCA assay. Homogenate of 50 ug was added to a process control of 800 ng of yeast enolase protein (Sigma) which was then reduced with 20 mM DTT and alklyated with 40 mM IAA. Lysates were then prepared for S-trap column (Protifi) binding by the addition of 1.2% phosphoric acid and 350 ul of binding buffer (90% Methanol, 100 mM TEAB). The acidified lysate was bound to column incrementally, followed by 3 wash steps with binding buffer to remove SDS and 3 wash steps with 50:50 methanol:chloroform to remove lipids and a final wash step with binding buffer. Trypsin (1:10) in 50mM TEAB was then added to the S-trap column for digestion at 47°C for one hour. Hydrophilic peptides were then eluted with 50 mM TEAB and hydrophobic peptides were eluted with a solution of 50% acetonitrile in 0.2% formic acid. Elutions were pooled, speed vacuumed and resuspended in 0.1% formic acid. A heavy labeled Peptide Retention Time Calibrant (PRTC) mixture (Pierce) was added to each sample. Liquid Chromatography and Mass Spectrometry - One ug of each sample with 150 femtomole of PRTC was loaded onto a 30 cm fused silica picofrit (New Objective) 75 µm column and 3.5 cm 150 µm fused silica Kasil1 (PQ Corporation) frit trap loaded with 3 µm Reprosil-Pur C18 (Dr. Maisch) reverse-phase resin analyzed with a Thermo Easy nano-LC 1200. The PRTC mixture is used to assess quality of the column before and during analysis. Four of these quality control runs are analyzed prior to any sample analysis and then after every six sample runs another quality control run is analyzed. Buffer A was 0.1% formic acid in water and buffer B was 0.1% formic acid in 80% acetonitrile. The 40-minute QC gradient consists of a 0 to 16% B in 5 minutes, 16 to 35% B in 20 minutes, 35 to 75% B in 1 minute, 75 to 100% B in 5 minutes, followed by a wash of 9 minutes and a 30 minute column equilibration. The 110-minute sample LC gradient consists of a 2 to 7% for 1 minutes, 7 to 14% B in 35 minutes, 14 to 40% B in 55 minutes, 40 to 60% B in 5 minutes, 60 to 98% B in 5 minutes, followed by a 9 minute wash and a 30 minute column equilibration. Peptides were eluted from the column with a 50°C heated source (CorSolutions) and electrosprayed into a Thermo Orbitrap Fusion Lumos Mass Spectrometer with the application of a distal 3 kV spray voltage. For the quality control analysis, a cycle of one 120,000 resolution full-scan mass spectrum (350-2000 m/z) followed by a data-independent MS/MS spectra on the loop count of 76 data-independent MS/MS spectra using an inclusion list at 15,000 resolution, AGC target of 4e5, 20 sec maximum injection time, 33% normalized collision energy with a 8 m/z isolation window. For the sample digest, first a chromatogram library of 6 independent injections is analyzed from a pool of all samples within a batch. For each injection a cycle of one 120,000 resolution full-scan mass spectrum with a mass range of 100 m/z (400-500 m/z, 500-600 m/z…900-1000 m/z) followed by a data-independent MS/MS spectra on the loop count of 26 at 30,000 resolution, AGC target of 4e5, 60 sec maximum injection time, 33% normalized collision energy with a 4 m/z overlapping isolation window. The chromatogram library data is used to quantify proteins from individual sample runs. These individual runs consist of a cycle of one 120,000 resolution full-scan mass spectrum with a mass range of 350-2000 m/z, AGC target of 4e5, 100 ms maximum injection time followed by a data-independent MS/MS spectra on the loop count of 76 at 15,000 resolution, AGC target of 4e5, 20 sec maximum injection time, 33% normalized collision energy with an overlapping 8 m/z isolation window. Application of the mass spectrometer and LC solvent gradients are controlled by the ThermoFisher XCalibur data system. Data Analysis - Thermo RAW files were converted to mzML format using Proteowizard (version 3.0.19045) using vendor peak picking and demultiplexing. Chromatogram spectral libraries were created using default settings (10 ppm tolerances, trypsin digestion, HCD b- and y-ions) of Walnut in EncyclopeDIA (version 0.9.0) using the Uniprot mouse canonical FASTA. Quantitative spectral libraries were created by mapping spectral to the chromatogram spectral library using EncyclopeDIA requiring a minimum of 3 quantitative ions and filtering peptides at a 1% FDR using Percolator 3.01. The quantitative spectral library is imported into Skyline with the mouse uniprot FASTA as the background proteome to map peptides to proteins. The mzML data is imported and all data is TIC normalized and calibrated to the batch reference.
Sample Description
Each sample batch was 24 individual mouse heart tissue samples, representing 4 randomly selected mice from 6 groups, and 2 pooled references for a total of 26 samples per batch. The first reference was a pool composed of 32 samples, 4 randomly selected mice from 8 groups (2 of the 8 groups not represented in this study). The second reference was a pool composed of 24 samples, 4 randomly selected mice from 6 groups (none of the 6 groups represented in this study). Both references were homogenized, aliquoted, frozen, and used to compare between batches and as a “universal reference” for comparison between similar proteomic studies. Six groups are: 1) Male-Sham-Young-Control, 2) Male-Sham-Old-Control, 3) Male-Sham-Old-Aca, 4) Female-Sham-Young-Control, 5) Female-Sham-Old-Control, 6) Female-Sham-Old-Aca. Reference 1 - Sham and Reference 2 - Cast
Created on 2/24/20, 3:54 PM
Clustergrammer Heatmap
 
Download
SPE_recovery_part 2.sky.zip2025-09-11 14:19:05224590266120
SPE recovery_part 1_A1AT, A1AG, IgA.sky.zip2025-09-11 14:19:056112266120
Intra- and interday precision_part 2.sky.zip2025-09-11 14:19:02224590274180
Intra- and interday precision_part 1_ A1AT, A1AG, IgA.sky.zip2025-09-11 14:19:026112267180
Proteomic analysis of 98 UCP samples.sky.zip2025-09-11 14:18:462856112340980
Proteomic analysis of 98 MP samples.sky.zip2025-09-11 14:18:462856112340980
Calibration_part 2.sky.zip2025-09-11 14:18:41224549144450
Calibration_part 1_A1AT, A1AG, IgA.sky.zip2025-09-11 14:18:396112264480
Standard_Add_2025-09-11_13-43-33.sky.zip2025-09-11 13:43:4723618250
Val_Stability_2025-09-11_13-42-55.sky.zip2025-09-11 13:43:02236182400
Val_Interference_2025-09-11_13-41-27.sky.zip2025-09-11 13:41:3323618450
ProINS_Imprecision_2025-09-11_13-40-32.sky.zip2025-09-11 13:40:4023618980
AbLotComparison_2025-09-11_13-39-42.sky.zip2025-09-11 13:39:4932824166
Buffers_Ab_2025-09-11_13-38-31.sky.zip2025-09-11 13:38:3713635220
IAA_peptides_2025-09-11_13-36-33.sky.zip2025-09-11 13:36:424312387910
Buffers_digest_2025-09-11_13-13-51.sky.zip2025-09-11 13:13:5813635220
PFAS and Autoimmune Disease Skyline Document - NTA and SSA_2025-09-02_11-27-20.sky.zip2025-09-02 15:17:5760292920329
PFAS and Autoimmune Disease Skyline Document - Absolute Quant_2025-09-02_11-26-32.sky.zip2025-09-02 15:17:5750535328618
TPAD_totalCSF-multiNF-DIANN_Batch8_annotated.sky.zip2025-08-28 12:23:582,50424,98830,183239,582540
humanMVs_expt3_pepsInAll3_2025-07-21_15-21-49.sky.zip2025-08-14 00:10:264,33830,60130,601211,479290
humanMVs_expt2_pepsInAll3_2025-07-21_15-14-15.sky.zip2025-08-14 00:10:264,33830,60130,601211,524210
humanMVs_expt1_pepsInAll3_2025-07-21_15-01-07.sky.zip2025-08-14 00:10:264,33830,60130,601209,463340
humanMVs_expt3_2025-07-21_14-42-08.sky.zip2025-08-14 00:10:266,07565,24665,246444,457290
humanMVs_expt2_2025-07-21_12-54-40.sky.zip2025-08-14 00:10:266,19360,86260,862421,246210
humanMVs_expt1_2025-07-21_12-28-41.sky.zip2025-08-14 00:10:265,76359,38259,382409,061340
METRIC_Eclipse_PSB_All_QCs_2025-08-08_23-10-58.sky.zip2025-08-08 20:11:0616662376
Kang_et_al_Proteomics_FigS3_2025-08-06_12-31-18.sky.zip2025-08-07 17:30:536181871300
ecoli_large_replicates_loaded_refined_2024-05-30_14-02-04.sky.zip2025-08-05 20:49:443669899894,94080
ecoli_large_replicates_loaded_2024-05-30_14-00-59.sky.zip2025-08-05 20:49:444611,3021,3027,52480
ecoli_large_replicates_2024-05-30_14-00-05.sky.zip2025-08-05 20:49:444611,3021,3027,52400
ecoli_subset_replicates_refined_cv_2024-05-30_13-58-18.sky.zip2025-08-05 20:49:447592,2662,26612,80720
ecoli_subset_replicates_refined_2024-05-30_13-57-25.sky.zip2025-08-05 20:49:447592,4372,43713,60220
ecoli_subset_replicates_2024-05-30_13-56-16.sky.zip2025-08-05 20:49:447592,4372,44130,85720
gpf_results_importer_2024-05-30_13-54-14.sky.zip2025-08-05 20:49:441,1925,3967,42785,67310
gpf_results_manual_2024-05-30_13-52-23.sky.zip2025-08-05 20:49:441,1925,3967,42785,67310
pq500_100spd_plasma_final_lightheavy_replicates_2024-05-30_13-50-10.sky.zip2025-08-05 20:48:155798181,62213,699100
pq500_60spd_plasma_final_lightheavy_replicates_2024-05-30_13-48-26.sky.zip2025-08-05 20:48:155798181,62213,876100
pq500_100spd_plasma_final_replicates_2024-05-30_13-47-38.sky.zip2025-08-05 20:48:155798188187,081100
pq500_60spd_plasma_final_replicates_2024-05-30_13-46-43.sky.zip2025-08-05 20:48:155798188186,977100
pq500_100spd_plasma_multireplicate_results_refined_2024-05-30_13-46-07.sky.zip2025-08-05 20:48:155798188187,08110
pq500_60spd_plasma_multireplicate_results_refined_2024-05-30_13-45-40.sky.zip2025-08-05 20:48:155798188186,97710
pq500_100spd_plasma_multireplicate_results_2024-05-30_13-45-07.sky.zip2025-08-05 20:48:155798188187,65120
pq500_60spd_plasma_multireplicate_results_2024-05-30_13-44-21.sky.zip2025-08-05 20:48:155798188187,60120
pq500_100spd_neat_multireplicate_results_refined_2024-05-30_13-43-42.sky.zip2025-08-05 20:48:155798188187,68910
pq500_60spd_neat_multireplicate_results_refined_2024-05-30_13-43-05.sky.zip2025-08-05 20:48:155798188187,60110
pq500_100spd_neat_multireplicate_results_2024-05-30_13-42-26.sky.zip2025-08-05 20:48:1557981881811,08810
pq500_60spd_neat_multireplicate_results_2024-05-30_13-41-26.sky.zip2025-08-05 20:48:1557981881811,08810
pq500_60spd_neat_multireplicate_2024-05-30_13-40-53.sky.zip2025-08-05 20:48:1557981881811,08800
Crossfeeding_PlateD.sky.zip2025-07-31 18:21:505012122470
Crossfeeding_PlateC.sky.zip2025-07-31 18:21:505012122470
Crossfeeding_PlateB.sky.zip2025-07-31 18:21:505012122470
Crossfeeding_PlateA.sky.zip2025-07-31 18:21:505012122470
Monoculture_Verruco25.sky.zip2025-07-31 18:21:505012121780
Monoculture_Flavo40.sky.zip2025-07-31 18:21:505012121620
Monoculture_Flavo56.sky.zip2025-07-31 18:21:495012121380
Monoculture_Verruco69.sky.zip2025-07-31 18:21:495012122040
Monoculture_Gamma88.sky.zip2025-07-31 18:21:495012121340
Monoculture_Flavo94.sky.zip2025-07-31 18:21:495012121460
Monoculture_Verruco4.sky.zip2025-07-31 18:21:495012121800
Monoculture_Flavo12.sky.zip2025-07-31 18:21:495012121900
PairwiseCoCultures_Verruco4.sky.zip2025-07-31 18:21:495012122470
PairwiseCoCultures_Verruco69.sky.zip2025-07-31 18:21:495012122470
PairwiseCoCultures_Verruco25.sky.zip2025-07-31 18:21:495012122470
Monoculture_AllStrains.sky.zip2025-07-31 18:21:495012122470
FucoidanDiversity_PlateF.sky.zip2025-07-31 18:21:495012122470
FucoidanDiversity_PlateE.sky.zip2025-07-31 18:21:498034341500
FucoidanDiversity_PlateD.sky.zip2025-07-31 18:21:495012121510
FucoidanDiversity_PlateC.sky.zip2025-07-31 18:21:498034341020
FucoidanDiversity_PlateB.sky.zip2025-07-31 18:21:495012121990
FucoidanDiversity_PlateA.sky.zip2025-07-31 18:21:498034341260
7DegraderCommunity_PlateD.sky.zip2025-07-31 18:21:495012122470
7DegraderCommunity_PlateC.sky.zip2025-07-31 18:21:495012122470
7DegraderCommunity_PlateA.sky.zip2025-07-31 18:21:495012122470
7DegraderCommunity_PlateB.sky.zip2025-07-31 18:21:495012122470
hela_2025-07-21_15-14-01.sky.zip2025-07-23 10:27:101,8379,1829,64986,73610
mouse_2025-07-21_15-13-32.sky.zip2025-07-23 10:27:101,4147,6538,39875,50710
yeast_2025-07-21_15-12-08.sky.zip2025-07-23 10:27:101756016525,86610
DSS Response curve_105plex_5repeats_2025-07-11_01-47-02.sky.zip2025-07-14 10:02:3296105220638600
210723-ATI-barley-Pt14_2025-02-24_01-08-00.sky.zip2025-07-02 20:45:2110101987330
210423-ATI-barley-Pt13_2025-02-24_01-07-11.sky.zip2025-07-02 20:45:2010101940270
210416-ATI-barley-Pt12_2025-02-24_01-06-33.sky.zip2025-07-02 20:45:1810101938430
210415-ATI-barley-Pt11_2025-02-24_01-05-41.sky.zip2025-07-02 20:45:1610101940290
210302-ATI-barley-Pt10_2025-02-24_01-05-05.sky.zip2025-07-02 20:45:1510101942340
210224-ATI-barley-Pt9_2025-02-24_01-04-22.sky.zip2025-07-02 20:45:1310101940310
210217-ATI-barley-Pt8_2025-02-24_01-03-46.sky.zip2025-07-02 20:45:1210101940290
210210-ATI-barley-Pt7_2025-02-24_01-03-02.sky.zip2025-07-02 20:45:1010101946310
210203-ATI-barley-Pt6_2025-02-24_01-02-20.sky.zip2025-07-02 20:45:0910101950310
210129-ATI-barley-Pt5_2025-02-24_01-01-22.sky.zip2025-07-02 20:45:0710101958310
200731-ATI-barley-Pt4_2025-02-24_01-00-26.sky.zip2025-07-02 20:45:0610101987190
200717-ATI-barley-Pt3_2025-02-24_00-58-01.sky.zip2025-07-02 20:45:0410101987550
200709-ATI-barley-Pt2-Response_2025-02-24_00-56-48.sky.zip2025-07-02 20:45:011010199570
200709-ATI-barley-Pt2_2025-02-24_00-55-11.sky.zip2025-07-02 20:45:0110101991360
200602-ATI-barley-Pt1_2025-02-24_00-25-35.sky.zip2025-07-02 20:44:5910101993310
TPAD_CSF1A_Batch1-multiNF-DIANN.sky.zip2025-07-01 17:49:472,85327,12832,575259,532430
TPAD_CSF1A_Batch1-multiNF-DIANN-grouped.sky.zip2025-07-01 17:41:312,67226,43931,769253,119430
TPAD_CSF1B_Batch2-multiNF-DIANN.sky.zip2025-07-01 15:26:132,85327,12832,575259,532410
TPAD_CSF1B_Batch2-multiNF-DIANN-grouped.sky.zip2025-07-01 15:17:422,67226,43931,769253,119410
TPAD_CSF2A_Batch3-multiNF-DIANN.sky.zip2025-07-01 14:13:302,85327,12832,575259,532430
TPAD_CSF2A_Batch3-multiNF-DIANN-grouped.sky.zip2025-07-01 14:04:582,67226,43931,769253,119430
TPAD_CSF2B_Batch4-multiNF-DIANN.sky.zip2025-07-01 11:21:372,85327,12832,575259,532430